Novel treatment strategies for malignant melanoma: A new beginning?

Critical Reviews in Oncology/Hematology

Volumn 62, Issue 1, 2007, Pages 16-22

  Kasper, Bernd ^a   D'Hondt, Veronique ^a   Vereecken, Pierre ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Malignant melanoma; Molecular targeted therapies; New treatment strategies

Indexed keywords

AG 014699; ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CP 675206; DACARBAZINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96; INO 1001; INTERLEUKIN 2; IPILIMUMAB; LENALIDOMIDE; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OBLIMERSEN; PACLITAXEL; RAPAMYCIN; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TICILIMUMAB; UNCLASSIFIED DRUG;

ANOREXIA; AUTOIMMUNE DISEASE; CLINICAL TRIAL; COLITIS; DERMATITIS; DIARRHEA; ENTEROCOLITIS; HUMAN; HYPOPHYSITIS; IMMUNOMODULATION; MELANOMA; MOLECULAR DYNAMICS; NAUSEA; NEUTROPENIA; NONHUMAN; PATHOGENESIS; POPULATION RESEARCH; PROGNOSIS; REVIEW; SKIN TOXICITY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 33847253876     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.11.007     Document Type: Review

References (68)

1. Armstrong B.K., and Kricker A. Cutaneous melanoma. Cancer Surv 19/20 (1994) 219-240
2. MacKie R.M., Bray C.A., Hole D.J., et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet 360 (2002) 587-591
3. Ahmed I. Malignant melanoma: prognostic indicators. Mayo Clin Proc 72 (1997) 356-361
4. Garbe C., Buttner P., Bertz J., et al. Primary cutaneous melanoma: identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75 (1995) 2484-2491
5. Miller B., Ries L., Hankey B., Kosary C., and Edwards B. Cancer statistics review: 1973-1989 (1992), US Department of Health and Human Services, Bethesda p. 92-278
6. Barth A., Wanek L.A., and Morton D.L. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181 (1995) 193-201
7. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
8. Voit C., Kron M., Rademaker J., et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol 23 (2005) 1218-1227
9. Dai D.L., Martinka M., and Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23 (2005) 1473-1482
10. Guerry D., and Schuchter L.M. Disseminated melanoma: is there a new standard therapy?. N Engl J Med 327 (1992) 560-561
11. Schadendorf D. Is there a standard for the palliative treatment of melanoma?. Onkologie 25 (2002) 74-76
12. Eigentler T.K., Caroli U.M., Radny P., and Garbe C. Palliative therapy of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials. Lancet Oncol 4 (2003) 748-759
13. Tarhini A.A., and Agarwala S.S. Novel agents in development for treatment of melanoma. Expert Opin Invest Drugs 14 (2005) 885-892
14. D'Amato R.J., Loughnan M.S., Flynn E., and Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91 (1994) 4082-4085
15. Keifer J.A., Guttridge D.C., Ashburner B.P., and Baldwin A.S. Inhibition of NF-κB activity by thalidomide through suppression of IκB kinase activity. J Biol Chem 276 (2001) 22382-22387
16. Marriott J.B., Clarke I.A., Dredge K., et al. Thalidomide and its analogous have distinct and opposing effects on TNF-α and TNFR2 during costimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 130 (2002) 75-84
17. Daliani D.D., Papandreou C.N., Thall P.F., et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95 (2002) 758-765
18. Bamias A., and Dimopoulos M.A. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opin Invest Drugs 14 (2005) 45-55
19. Eisen T., Boshoff C., Maki I., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82 (2000) 812-817
20. Reiriz A.B., Richter M.F., Fernandes S., et al. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 14 (2004) 527-531
21. Pawlak W.Z., and Legha S.S. Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res 14 (2004) 57-62
22. Hwu W.J., Krown S.E., Menell J.H., et al. Phase II study of temozolomide plus thalidomide for the treatment of metatstaic melanoma. J Clin Oncol 21 (2003) 3351-3356
23. Hwu W.J., Lis E., Menell J.H., et al. Temozoomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103 (2005) 2590-2597
24. Danson S., Lorigan P., Arance A., et al. Randomized phase II study of temozolomide given every 8 h or daily with either interferon α or thalidomide in metastatic malignant melanoma. J Clin Oncol 21 (2003) 2551-2557
25. Payvandi F., Wu L., Haley M., et al. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-alpha, IL-1beta, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cell Immunol 230 (2004) 81-88
26. Bartlett J.B., Michael A., Clarke I.A., et al. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 90 (2004) 955-961
27. Gerber H.P., and Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 64 (2005) 671-680
28. Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59 (1999) 1693s-1700s
29. Jansen B., Schlagbauer-Wadl H., Brown B.D., et al. Bcl-2 antisense therapy chemosensitizes melanoma in SCID mice. Nat Med 4 (1998) 232-234
30. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
31. Piro L.D. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston Park) 18 (2004) 5-10
32. Stein C.A., Benimetskaya L., and Mani S. Antisense strategies for oncogene inactivation. Semin Oncol 32 (2005) 563-572
33. Danson S., and Lorigan P. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs 65 (2005) 733-743
34. Ugurel S., and Schadendorf D. Systemic treatment in advanced melanoma: innovative perspectives. Onkologie 26 (2003) 234-238
35. Gray-Schopfer V.C., da Rocha Dias S., and Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 24 (2005) 165-183
36. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
37. Shinozaki M., Ujimoto A., Morton D.L., and Hoon D.S. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10 (2004) 1753-1757
38. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 23 (2004) 6292-6298
39. Wilhelm S.M., Carter C., Tang L., et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
40. Panka D.J., Wang W., Atkins M.B., and Mier J.W. The Raf inhibitor BAY 43-9006 (sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66 (2006) 1611-1619
41. Strumberg D., Richly H., Hilger R.A., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY-43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23 (2005) 695-972
42. Strumberg D, Awada A, Hirte H, et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? Eur J Cancer 2006 [Epub ahead of print].
43. Ahmad T., and Eisen T. Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10 (2004) 6388s-6392s
44. D'Hondt V., Gil T., Lalami Y., Piccart M., and Awada A. Will the dark sky over advanced renal cell carcinoma soon become brighter?. Eur J Cancer 41 (2005) 1246-1253
45. Ahmad T., Marais R., Pyle L., et al. BAY-43-9006 in patients with advanced melanoma: the Royal Marsden experience. Proc Am Soc Clin Oncol (2004) 711s
46. Flaherty K., Brose M., Schluchter L., et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma. Proc Am Soc Clin Oncol (2004) 711s
47. Flaherty K.T. New molecular targets in melanoma. Curr Opin Oncol 16 (2004) 150-154
48. Molhoek K.R., Brautigan D.L., and Slingluff C.L. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor rapamycin. J Trans Med 3 (2005) 39
49. Blachere N.E., and Srivastava P.K. Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors. Semin Cancer Biol 6 (1995) 349-355
50. Rivoltini L., Castelli C., Carrabba M., et al. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells. J Immunol 171 (2003) 3467-3474
51. Belli F., Testori A., Rivoltini L., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunological findings. J Clin Oncol 20 (2002) 4169-4180
52. Pilla L., Patuzzo R., Rivoltini L., et al. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother 8 (2005) 1-11
53. Kapadia D., and Fong L. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 23 (2005) 8926-8928
54. Chambers C.A., Kuhns M.S., Egen J.G., and Allison J.P. CTLA-4 mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 19 (2001) 565-594
55. Tivol E.A., Borriello F., Schweitzer A.N., et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
56. Leach D., Krummel M., and Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996) 1734-1736
57. Hurwitz A.A., Foster B.A., Kwon E.D., et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 60 (2000) 2444-2448
58. Ribas A., Camacho L.H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte associate antigen-4 monoclonal antibody CP-675,206. J Clin Oncol 23 (2005) 8968-8977
59. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100 (2003) 4712-4717
60. Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005) 741-750
61. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23 (2005) 6043-6053
62. Maker A.V., Phan G.Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12 (2005) 1005-1016
63. Woon E.C., and Threadgill M.D. Poly(ADP-ribose)polymerase inhibition-where now?. Curr Med Chem 12 (2005) 2373-2392
64. Graziana G., and Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 52 (2005) 109-118
65. Tentori L., Leonetti C., Scarsella M., et al. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin Cancer Res 9 (2003) 5370-5379
66. Tentori L., Leonetti C., Scarsella M., et al. Poly(ADP-ribose) glycolhydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Clin Cancer Res 41 (2005) 2948-2957
67. Plummer R, Middletown M, Wilson R. First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (PTS) with advanced solid tumors. Proc Am Soc Clin Oncol 2005 [Abstract 3065].
68. Markovic S.N., Geyer S.M., Dawkins F., et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103 (2005) 2584-2589